Technology & Innovation

Impact of Continuous Glucose Monitoring (CGM) on BGM Market Share

The rise of Continuous Glucose Monitoring (CGM) is actively cannibalizing the traditional Blood Glucose Monitoring (BGM) market, fundamentally altering the economics of diabetes care.

  • Economic Shift: The industry is moving from a high-volume consumable model (test strips) to a high-value subscription model (sensors). While BGM revenues are declining in developed markets, CGM revenues are surging.
  • Adoption Dynamics: T1D and insulin-intensive T2D populations are rapidly abandoning routine finger-sticks for CGMs due to superior data and reimbursement expansion. BGM usage in these groups has dropped by up to 90%, serving only as a backup.
  • Market Resilience: BGM remains dominant in non-insulin T2D and emerging markets due to lower costs. Furthermore, test strips remain essential for sensor calibration, verifying outliers, and covering sensor warm-up periods, preventing total obsolescence.
  • Manufacturer Impact: Companies without CGM portfolios (LifeScan, Ascensia) are pivoting to digital health solutions and emerging markets, while hybrid companies (Abbott, Roche) manage the internal transition from strips to sensors.
1 min read
Intermediate
7 glossary terms
2 citations

Revolutionizing Diabetes Care with CGM

The Continuous Glucose Monitoring (CGM) revolution is here! It's changing how we manage blood glucose levels.

A Shift in the Market

The industry is moving from high-volume consumables to high-value subscriptions.

  • CGM revenues are surging, while BGM revenues decline in developed markets [1].
  • This shift is driven by the benefits of CGM, including improved glucose control and reduced hypoglycemia.

Who's Adopting CGM?

  • People with type 1 diabetes and insulin-intensive type 2 diabetes are ditching routine finger-sticks for CGMs [2].
  • They're drawn to the superior data and expanding reimbursement options.
  • BGM usage in these groups has dropped by up to 90% - it's now mainly used as a backup [3].

Where BGM Still Dominates

  • BGM remains the top choice in non-insulin type 2 diabetes and emerging markets due to lower costs [4].
  • Test strips are still essential for sensor calibration, verifying outliers, and covering sensor warm-up periods [5].

How Manufacturers Are Adapting

  • Companies without CGM portfolios are pivoting to digital health solutions and emerging markets [6].
  • Hybrid companies are navigating the transition from strips to sensors [7].

References

  1. Global Continuous Glucose Monitoring Market Size Report, 2030Source
  2. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetesSource

Was this article helpful?

Explore More Topics

Continue your research with related categories